CervoMed Inc. reported its financial results for the first quarter ended March 31, 2025, on May 12, 2025. The company's cash, cash equivalents, and marketable securities totaled approximately $35.2 million as of March 31, 2025, which is projected to fund operating expenses and capital expenditure requirements into mid-2026.
The net loss for the first quarter of 2025 was approximately $4.9 million, an increase from $2.5 million in the same period in 2024. Research and development (R&D) expenses increased to $4.8 million from $2.8 million year-over-year, driven by chemistry, manufacturing, and controls (CMC) activities, non-clinical studies, and costs for new Phase 2a trials.
CervoMed reiterated the positive 16-week results from the extension phase of the RewinD-LB trial, affirming proof-of-concept for neflamapimod in DLB. The company plans to initiate a Phase 3 trial in DLB in mid-2026 and has initiated a Phase 2 trial in ischemic stroke, with plans for another Phase 2a trial in primary progressive aphasia (PPA) in mid-2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.